A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

Locations

United States

Start date

02/12/2024

Identifiers

Trial ID NN9838-8259,
NCT number NCT06716307,
Eudract number Not Available

Summary

This study will compare the blood levels of cagrilintide and semaglutide when the same dose is given in two different versions of CagriSema. CagriSema is a medicine that combines two medicines called cagrilintide and semaglutide. It is still being tested in studies and is not yet available for doctors to prescribe. Participants will get an injection with each of the two versions of CagriSema at two different times at the clinic. Like all medicines, the study medicine may have side effects. The study will last for about 18 weeks.

Trial Overview:

Condition

Obesity

Treatment

DRUG: CagriSema (cagrilintide B and semaglutide I)

DRUG: CagriSema A

Study type

INTERVENTIONAL

Trial duration

Dec 02 2024 - Apr 14 2025

Participants

Phase

Are you eligible?

Gender

Male and female

Age

18 to 64 years old

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

Find answers in our FAQs

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.